Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19

Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16.

Authors

S Gevers¹, M S G Kwa², E Wijnans², C van Nieuwkoop³

Affiliations

¹ Dutch Medicines Evaluation Board, Utrecht, the Netherlands. Electronic address: s.gevers@cbg-meb.nl.
² Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
³ Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Haga Teaching Hospital, Department of Internal Medicine, The Hague, the Netherlands.

No abstract available

Publication types

Letter

MeSH terms

Antiviral Agents / administration & dosage
Antiviral Agents / adverse effects*
Antiviral Agents / pharmacokinetics
Betacoronavirus / drug effects*
COVID-19
COVID-19 Drug Treatment
Chloroquine / administration & dosage
Chloroquine / adverse effects*
Chloroquine / pharmacokinetics
Chloroquine / therapeutic use
Coronavirus Infections / drug therapy*
Humans
Hydroxychloroquine / administration & dosage
Hydroxychloroquine / adverse effects*
Hydroxychloroquine / pharmacokinetics
Hydroxychloroquine / therapeutic use
Pandemics
Pneumonia, Viral / drug therapy*
Randomized Controlled Trials as Topic
SARS-CoV-2

Substances

Antiviral Agents
Hydroxychloroquine
Chloroquine